Superworth

Autolus Therapeutics price to book ratio AUTL

Market value divided by the book value of the company's net assets, since 2023.

Today, Nov 2, 2026
5.1×
3-year median
1.9×
Against its 3-year history
77th
percentile: 0 is its lowest day, 100 its highest
3-year range
0.8× to 15.2×
Peer median
4.9×

Autolus Therapeutics' price to book ratio is 5.1× as of Nov 2, 2026.

That is above its 3-year median of 1.9×, higher than on 77% of days in the last 3 years.

Over that time it ranged from 0.8× in Apr 2025 to 15.2× in Mar 2024.

The median for 4 biotech stocks of a similar size is 4.9×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far5.1×1.2×8.6×
20251.7×0.8×1.8×
20241.3×1.3×15.2×
20236.2×3.3×6.2×

Against its peers

Companies in Biotechnology nearest Autolus Therapeutics' size, closest first, today.

CompanyPrice to book ratio
AUTLAutolus Therapeutics5.1×
PLXProtalix BioTherapeutics2.9×
MGTXMeiraGTx4.2×
VCELVericel5.6×
ADMAAdma Biologics6.1×
Peer median4.9×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Autolus Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.